CRL — Charles River Laboratories International, Inc.

Sentiment flipped decisively on 2026-08-05, when CRL beat on both lines ($1.00B revenue vs. ~$976M consensus; $3.02 non-GAAP EPS vs. ~$2.74) and management raised full-year revenue, non-GAAP EPS ($11.15-$11.45) and FCF ($400-420M) guidance - the stock jumped 12% in one session. The tell was operational, not just financial: DSA net book-to-bill climbed to ~1.2x, the third consecutive quarter of improvement, and organic revenue finally crossed zero (+0.1%). Sell-side has followed: consensus is 'Buy' with 27 buy/strong-buy ratings against 10 holds and zero sells, and a 12-month price target consensus of $277.60 (range $219-$320). As of 2026-09-13 the tape shows the excitement cooling into digestion rather than reversal - the stock is -3.55% over the past week and -2.15% over the past month, and RSI at 51.2 is dead-neutral, which is remarkable given the 6-month gain and suggests consolidation, not distribution.

Revenue has been on a plateau, not a decline, for three years: Q3 2023 $1,026.6M -> Q4 2023 $1,013.5M -> Q1 2024 $1,011.6M -> Q2 2024 $1,026.1M -> Q3 2024 $1,009.8M -> Q4 2024 $1,002.5M -> Q1 2025 $984.2M (the trough) -> Q2 2025 $1,032.1M -> Q3 2025 $1,004.9M -> Q4 2025 $994.2M -> Q1 2026 $995.8M -> Q2 2026 $1,004.1M. On a YoY basis that is roughly -0.5% to +1.2% every quarter for twelve quarters - a genuine flatline. Q2 2026 revenue was -2.7% YoY on a reported basis, but management reported organic growth of +0.1%, meaning FX and portfolio moves, not demand, are behind most of the reported gap. Margins tell a clearer trough-and-recover story: gross margin fell from 35.2% in Q3 2023 to a 28.0% air-pocket in Q1 2026 (likely tied to the Endosafe production-suite modernization), then snapped back to 36.2% in Q2 2026 - the highest gross margin in the entire 12-quarter data set. Operating margin compressed from 14.8% (Q3 2023) to 7.6% (Q1 2025), then recovered to a stable 11.9-13.3% band across Q3 2025 through Q2 2026, with four straight quarters at roughly 12%. GAAP earnings are distorted and should be ignored at face value: Q4 2024 lost $215.7M (-$4.22) and Q4 2025 lost $276.6M (-$5.62), both apparently impairment-driven, which is why TTM EPS is -$4.918 and the trailing P/E is -57.5. Cash generation is the cleanest signal and it is healthy: operating cash flow was positive in all twelve quarters, TTM free cash flow is $370.6M, and the accruals ratio of -2.41% (as of 2026-06-27) confirms cash earnings are running ahead of reported net income. Net verdict: a cyclical trough with one quarter of hard evidence of inflection - real, but not yet a confirmed trend.

The trailing metrics are unusable and should not be quoted as if they mean something: P/E TTM of -57.5 and EPS TTM of -$4.918 are artifacts of impairment charges, and the 5-year average P/E of 256.89 (4 years used) is a statistical ghost of near-zero earnings years. On the metrics that do work, CRL is fairly valued to modestly full. Against FY2026 non-GAAP EPS guidance midpoint of $11.30, the $278.26 price (as of 2026-09-13) is ~24.6x; against the FMP next-FY consensus EPS of $11.319 it is ~24.6x; against my own FY2027 estimate of ~$12.45 (mid-single-digit revenue growth plus ~60-80bp of margin recovery and ~2% share shrink) it is ~22.4x. That is mid-range versus CRL's own history (25-30x forward in 2020-21, ~18-20x in the 2023-24 de-rating). On sales, the $13.4B market cap on ~$4.0B of revenue gives P/S of 3.352 versus a 5-year average of 3.19 - slightly above its own average, not cheap. P/B of 4.75 overstates the multiple because book equity has been shrinking from $3.78B (Sep 2024) to $2.84B (Jun 2026) through impairments and buybacks. The PEG of 0.6 that anchors the deterministic score's 'Cheap vs. its own history' badge is measuring growth off a depressed base and is the weakest link in that conclusion. Bottom line: you are paying roughly 24.6x current-year guidance and ~19x normalized EBITDA for a business with flat trailing revenue and an unproven one-quarter recovery.

This is a stock that has already been paid for the recovery it is only now starting to deliver. Price is +79% over six months and +48.4% over three months (as of 2026-09-13), while reported revenue is still -2.7% YoY and GAAP EPS is negative - the market is underwriting the second derivative (book-to-bill, organic growth turning positive), not the current income statement. That means the stock is priced for confirmation, not for hope, which cuts both ways: if Q3 2026 (early-to-mid November) shows book-to-bill holding at or above 1.1-1.2x and revenue growth durably positive, the FY2027 consensus of roughly $11.32 will look stale and the multiple has room; if organic growth slips back to zero or negative, there is no earnings cushion at 24.6x to absorb the disappointment, since the forward estimate itself assumes the inflection. Practical read: this is a 'prove it' setup, not a deep-value entry. The asymmetry favors adding on confirmation rather than on anticipation.

As of 2026-09-13, RSI-14 stood at 51.2 - neutral, and notably NOT overbought despite the 79% six-month move, which means momentum has reset through time/consolidation rather than through a sharp selloff. The moving-average structure is bullish and stacked: price of $278.26 sits 7.48% above the 50-day SMA (approximately $259) and 37.46% above the 200-day SMA (approximately $202), while sitting 3.32% BELOW the 20-day SMA (approximately $288). That combination - below the short-term average, well above the medium and long-term averages - describes a healthy pullback inside an uptrend, not a breakdown. The 52-week range of $144.26-$303.31 puts the stock about 8% off its high. Timing implication: chasing here is buying into short-term resistance near $288; the better risk-defined zone is the $258-262 area around the 50-day, which is also roughly where my own fair-value estimate lands.

• Biotech funding cycle: CRL's DSA bookings are directly levered to venture-capital and early-stage biotech R&D budgets, which have been in a multi-year slump; the third straight quarter of improving book-to-bill (to ~1.2x) is the first real evidence of normalization, and a sustained thaw would be the single largest earnings driver.
• Interest rates and cost of capital: a rate-sensitive, cash-burning small-biotech customer base means any easing in 2026-2027 disproportionately boosts the preclinical demand funnel, while CRL's own $2.62B long-term debt against $192M of cash makes its cost of capital a two-sided factor.
• Non-human primate (NHP) supply: a chronic structural constraint and pricing wildcard in research models; CRL's controlling-stake acquisitions and internal sourcing (Noveprim, K.F. assets) have made it less exposed than peers, but any supply shock still moves segment margins.
• China/geopolitical and pharma pricing policy: exposure to Chinese customers plus evolving export-control and drug-pricing pressure on large-pharma R&D budgets (IRA, most-favored-nation pricing) are persistent overhangs on the multi-year revenue trajectory.
• FX translation: reported revenue is running ~2-3 points below organic (Q2 2026 reported -2.7% vs. organic +0.1%), so dollar strength is a steady, non-operational drag on the headline numbers.
• Tightening regulatory quality standards for biologics are a structural tailwind for the Manufacturing Solutions franchise (microbial testing, Endosafe endotoxin, NGS/PathoQuest), raising the value of specialized outsourced testing.

• Q3 2026 earnings (typically early-to-mid November 2026) - the single most important checkpoint; investors need to see book-to-bill stay near 1.2x and organic growth remain positive for a second consecutive quarter.
• Further guidance raises or upward consensus revisions - FY2026 non-GAAP EPS guidance was already lifted to $11.15-$11.45 and FCF to $400-420M on 2026-08-05; a second raise would validate the inflection.
• Management appearances at the Morgan Stanley and Baird healthcare conferences in September 2026, which could deliver qualitative color on order velocity and biotech client behavior between earnings dates.
• Margin recovery levers: the modernized Endosafe endotoxin production suite (completed September 2026) and NGS/PathoQuest integration, both of which could lift the depressed gross margin further from Q2 2026's 36.2%.
• Capital deployment: with $400-420M of guided FCF and D/E of 1.07, deleveraging or an accelerated buyback would add per-share earnings without requiring any revenue acceleration.
• A broader biotech funding thaw or rate-cut cycle, which would show up first as higher DSA bookings and faster book-to-bill conversion.

• One quarter is not a trend: organic growth of +0.1% in Q2 2026 is barely distinguishable from zero, and revenue has been flat at roughly $1.0B/quarter for twelve quarters. A relapse to negative organic growth would puncture the recovery narrative at a stock trading ~24.6x current-year guidance EPS.
• Impairment and GAAP-quality risk: two consecutive Q4 write-downs ($215.7M in Q4 2024, $276.6M in Q4 2025) show the acquisition-built balance sheet carries real goodwill risk, and another charge would keep GAAP earnings negative and complicate the story.
• Leverage: $2.62B of long-term debt against only $192M of cash, debt-to-equity of 1.066 and net debt of roughly $2.43B. Any EBITDA disappointment or rate shock hits equity holders disproportionately.
• Valuation/multiple compression: after a 79% six-month run, the stock is priced for a recovery that the income statement has not yet delivered, and P/S of 3.352 is already slightly above the 5-year average of 3.19 - there is little valuation cushion for a miss.
• End-market dependence: CRL sells into client R&D budgets. A biotech funding relapse, large-pharma R&D austerity, or adverse drug-pricing policy (IRA, MFN) would hit DSA bookings with a lag before revenue.
• Structural supply and geopolitical exposure: NHP availability and pricing, plus China-related demand and regulatory/tariff friction, remain outside management's control.
• Competitive insourcing: large pharma periodically pulls preclinical work back in-house, and competitors (IQVIA, Labcorp/Fortrea, Evotec) compete for the same outsourced budgets on price.

CRL is a genuinely high-quality, essential-infrastructure franchise coming off a cyclical trough, and the green shoots are real: three consecutive quarters of improving book-to-bill to ~1.2x, the first positive organic growth since Q3 2023, gross margin snapping back to a 12-quarter high of 36.2% in Q2 2026, a broad guidance raise, and $370.6M of TTM free cash flow with a clean -2.41% accruals ratio. The problem is that the market has already noticed - the stock is up 79% in six months and trades at ~24.6x FY2026 guidance EPS with a P/S slightly above its own 5-year average - so the recovery is largely in the price. I like the business and the direction, but at $278.26 as of 2026-09-13 the risk/reward is balanced rather than compelling: I would want Q3's confirmation (or a pullback toward the ~$259 50-day average) before paying up. This is analysis, not personalized financial advice.

Blended multiple approach, run as of 2026-09-13. Primary anchor: 21x my FY2027E non-GAAP EPS of $12.45 (built from FY2026 guidance midpoint of $11.30 plus mid-single-digit revenue growth, ~60-80bp of operating-margin recovery, lower interest expense and ~2% share-count reduction) = $261.50; 21x sits below CRL's 2015-2021 forward multiple of 25-30x and above the 2023-24 de-rating trough of 18-20x, appropriate for a confirmed-but-early inflection. Cross-checks: 18.5x normalized EBITDA of ~$815M (TTM operating income of $493.8M plus ~$320M D&A) against a $15.8B enterprise value minus $2.43B net debt = ~$254; and a 3.6% normalized FCF yield on ~$455M (guided FY2026 FCF of $400-420M, adjusted for normalized capex) = ~$264. Average of the three, ~$261.